Resources from the same session
LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
Presenter: Cécile Le Pechoux
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA4 - IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
610O - Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Presenter: Johann de Bono
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA5_PR - Abemaciclib in high risk early breast cancer
Presenter: Stephen Johnston
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA3_PR
Presenter: Rafal Dziadziuszko
Session: Presidential Symposium II
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Solange Peters
Session: Presidential Symposium II
Resources:
Webcast
Invited Discussant LBA4 and 610O
Presenter: Henrik Grönberg
Session: Presidential Symposium II
Resources:
Slides
Webcast
Q&A live discussion
Presenter: Solange Peters
Session: Presidential Symposium II
Resources:
Webcast
Q&A and live discussion
Presenter: Solange Peters
Session: Presidential Symposium II
Resources:
Webcast